Last reviewed 2026-05-15 · How we verify

Combination carboplatin and paclitaxel

Combination carboplatin and paclitaxel is a Chemotherapy combination (platinum agent + taxane) Small molecule drug developed by OSI Pharmaceuticals. It is currently in Phase 3 development for Non-small cell lung cancer, Ovarian cancer, Breast cancer. Also known as: carboplatin , paclitaxel and Gemcitabine, Carboplatin, Paclitaxel, Paraplatin.

This combination uses carboplatin to cross-link DNA and paclitaxel to stabilize microtubules, together inducing cancer cell death through complementary cytotoxic mechanisms.

This combination uses carboplatin to cross-link DNA and paclitaxel to stabilize microtubules, together inducing cancer cell death through complementary cytotoxic mechanisms. Used for Non-small cell lung cancer, Ovarian cancer, Breast cancer.

At a glance

Mechanism of action

Carboplatin is a platinum-based alkylating agent that forms DNA adducts, preventing replication and transcription. Paclitaxel is a taxane that binds β-tubulin and prevents microtubule depolymerization, disrupting mitotic spindle formation. Together, they provide synergistic cytotoxicity against rapidly dividing cancer cells.

Approved indications

• Non-small cell lung cancer
• Ovarian cancer
• Breast cancer

Common side effects

• Neutropenia
• Anemia
• Thrombocytopenia
• Peripheral neuropathy
• Nausea/vomiting
• Alopecia
• Fatigue
• Hypersensitivity reactions

Key clinical trials

• Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
• Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
• A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
• Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
• Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] (PHASE3)
• Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (PHASE1)
• A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Combination carboplatin and paclitaxel CI brief — competitive landscape report
• Combination carboplatin and paclitaxel updates RSS · CI watch RSS
• OSI Pharmaceuticals portfolio CI

Frequently asked questions about Combination carboplatin and paclitaxel

Related

• Drug class: All Chemotherapy combination (platinum agent + taxane) drugs
• Target: All drugs targeting DNA (carboplatin); β-tubulin (paclitaxel)
• Manufacturer: OSI Pharmaceuticals — full pipeline
• Therapeutic area: All drugs in Oncology
• Indication: Drugs for Non-small cell lung cancer
• Indication: Drugs for Ovarian cancer
• Indication: Drugs for Breast cancer
• Also known as: carboplatin , paclitaxel and Gemcitabine, Carboplatin, Paclitaxel, Paraplatin, Taxol
• Compare: Combination carboplatin and paclitaxel vs similar drugs
• Pricing: Combination carboplatin and paclitaxel cost, discount & access